20 Jun Next-Generation Cologuard Test Demonstrates 94 Percent Sensitivity For Colorectal Cancer At 91 Percent Specificity, Raising The Bar In Non-Invasive Screening
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced positive top-line results from the pivotal BLUE-C study. "Cologuard is a groundbreaking innovation in non-invasive cancer detection. Next-generation Cologuard will set a new performance standard," said Kevin Conroy, chairman and CEO...